Related Experiment Video
Updated: Jun 7, 2025
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Bacterial profile and antimicrobial susceptibility patterns of common neonatal sepsis pathogens in Gulf Cooperation
Muhammad Candragupta Jihwaprani1, Idris Sula2, Daniel Coha2
1Department of Pediatrics, Sidra Medicine, Doha, Qatar.
Introduction:
Neonatal sepsis (NS) is a major healthcare burden in Gulf Cooperation Council (GCC) countries, with a prevalence higher than the global average. Microbial drug resistance has major implications for mortality and morbidity from NS.
Objective:
To synthesize data regarding the patterns of causative bacteria of NS in the GCC and their antimicrobial susceptibility profiles.
Methods:
Following the exploration of four electronic databases, i.e., EBSCOhost, ProQuest, PubMed/MEDLINE, and ScienceDirect, eligible studies were identified (i.e., published between 2013 and 2023 and reported bacterial profile and/or antimicrobial susceptibility patterns). The outcomes included the pooled prevalence of bacteria and their susceptibility patterns. Proportion meta-analysis was performed for each outcome of interest.
Results:
Fifteen studies were eligible (total positive cases = 2,473). Coagulase-negative Staphylococci (CoNS) (28.1%) were the most common gram-positive causative pathogen, followed by group B Streptococcus (GBS) (16.2%) and Staphylococcus aureus (9.9%); for gram-negative, Escherichia coli (12.7%) and Klebsiella species (11.4%) were most common. The susceptibility rates of these bacteria to first-line antibiotics were high; gram-positive bacteria had the highest susceptibility to ampicillin (72.8-98%), and gram-negative bacteria was most susceptible to amikacin (94.6-98%). Additionally, both gram-positive (67-77%) and negative (87-93%) bacteria exhibited high susceptibility to gentamicin.
Conclusion:
The most common pathogens among NS patients were gram-positive. The pathogens, irrespective of stain test, were susceptible to the current antibiotic therapy. We recommend the judicious use of empirical antibiotic therapy to prevent the growing risk of antimicrobial resistance.
